Validation of MELD3.0 in 2 centers from different continents.

Marta TejedorJosé María BellónMargarita Fernández de la VargaPeregrina PeraltaEva MontalváGonzalo Sapisochin Marina C Berenguer

Published in: Hepatology communications (2024)

MELD3.0 has been validated in centers with significant heterogeneity and offers the highest mortality prediction for women on the WL without disadvantaging men. However, in these cohorts, it was not superior to MELDNa.

Keyphrases

polycystic ovary syndrome
cardiovascular events
single cell
pregnancy outcomes
risk factors
type diabetes
cervical cancer screening
cardiovascular disease
coronary artery disease
pregnant women
adipose tissue